RxDoctor Payments Data

Thomas Mustoe, MD

Interventional Cardiology · Salinas, CANPI 1952309908

Payments from drug & device makers

$17,914in general payments, 2019–2025

Across 790 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Novartis$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • plus $10K from 46 others

What the payments were for

  • Travel & lodging$8775%
  • Food & beverage$16,86294%
  • Education$1751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,914 in reported general payments places this provider in the 60th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$376,967
Medicare patients
2,541
Services billed
6,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$483,526
JardianceEmpagliflozin273$295,316
XareltoRivaroxaban135$197,243
EntrestoSacubitril/Valsartan123$158,125
FarxigaDapagliflozin Propanediol86$66,348
Repatha SureclickEvolocumab46$57,403
BrilintaTicagrelor39$40,881
MultaqDronedarone Hcl22$30,977
Ezetimibe671$25,402
Atorvastatin Calcium1,490$19,234
VerquvoVericiguat23$18,603
OzempicSemaglutide14$17,218
KerendiaFinerenone17$13,619
Propafenone Hcl111$11,290
VascepaIcosapent Ethyl14$10,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$459$483,526379 claims
Boehringer IngelheimJardiance$1,148$295,316273 claims
Johnson & JohnsonXarelto$510$197,243135 claims
NovartisEntresto$1,274$158,125123 claims
AstraZenecaFarxiga, Brilinta$1,178$107,229125 claims
Sanofi-aventis U.S. LLCMultaq$199$30,97722 claims
MerckVerquvo$634$18,60323 claims
Novo NordiskOzempic$1,222$17,21814 claims
BayerKerendia$487$13,61917 claims
Esperion Therapeutics, Inc.Nexletol$108$8,76215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →